Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12

AUTHORS

Liliane Hobeika, Sally E Self, Juan Carlos Q Velez

ABSTRACT

BACKGROUND: Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy. A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma. CASE PRESENTATION: A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria. His kidney function remained stable. Kidney biopsy findings were consistent with thrombotic microangiopathy. Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved. Due to progression of multiple myeloma, he died a few months later. CONCLUSION: In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient. More... »

PAGES

156

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2369-15-156

DOI

http://dx.doi.org/10.1186/1471-2369-15-156

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1047232947

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25267524


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Kidney Injury", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Boronic Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bortezomib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dexamethasone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Edema", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fatal Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension, Renal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lenalidomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Podocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteasome Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteinuria", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Shock, Septic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Teniposide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thalidomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thrombotic Microangiopathies", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Louisville", 
          "id": "https://www.grid.ac/institutes/grid.266623.5", 
          "name": [
            "Division of Nephrology and Hypertension, Department of Medicine, University of Louisville, 615 South Preston Street, 40202, Louisville, KY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hobeika", 
        "givenName": "Liliane", 
        "id": "sg:person.01027631644.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027631644.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical University of South Carolina", 
          "id": "https://www.grid.ac/institutes/grid.259828.c", 
          "name": [
            "Department of Pathology, Medical University of South Carolina, Charleston, SC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Self", 
        "givenName": "Sally E", 
        "id": "sg:person.015017370564.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015017370564.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical University of South Carolina", 
          "id": "https://www.grid.ac/institutes/grid.259828.c", 
          "name": [
            "Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Velez", 
        "givenName": "Juan Carlos Q", 
        "id": "sg:person.01131201727.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131201727.91"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bmt.1701171", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006660654", 
          "https://doi.org/10.1038/sj.bmt.1701171"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1701171", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006660654", 
          "https://doi.org/10.1038/sj.bmt.1701171"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/10428190802023707", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009669974"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bcr-2012-006461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011174364"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1046/j.1523-1755.2003.00071.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012605076", 
          "https://doi.org/10.1046/j.1523-1755.2003.00071.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1523-1755.2003.00071.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012605076"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3346/jkms.2014.29.5.648", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013160147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semnephrol.2010.09.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019546282"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.ki.5000055", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020678317", 
          "https://doi.org/10.1038/sj.ki.5000055"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc780", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024581782", 
          "https://doi.org/10.1038/nrc780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc780", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024581782", 
          "https://doi.org/10.1038/nrc780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.beha.2007.09.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025914764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1745-6215-15-107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026028815", 
          "https://doi.org/10.1186/1745-6215-15-107"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ndt/gft465", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028765304"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4081/hr.2012.e13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028803821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4081/hr.2012.e13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028803821"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/qjmed/89.10.751", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031036405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-008-0140-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032870534", 
          "https://doi.org/10.1007/s12185-008-0140-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-008-0140-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032870534", 
          "https://doi.org/10.1007/s12185-008-0140-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/petr.12300", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033543085"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.humpath.2014.05.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034050093"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1445-5994.2011.02458.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035735607"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0707330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036840499"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1701830", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037910558", 
          "https://doi.org/10.1038/sj.bmt.1701830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1701830", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037910558", 
          "https://doi.org/10.1038/sj.bmt.1701830"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1700791", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038194035", 
          "https://doi.org/10.1038/sj.bmt.1700791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1700791", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038194035", 
          "https://doi.org/10.1038/sj.bmt.1700791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2215/cjn.02070508", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038375943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1981.154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040267576", 
          "https://doi.org/10.1038/clpt.1981.154"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-4086", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047843351"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1702849", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050017834", 
          "https://doi.org/10.1038/sj.bmt.1702849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci115629", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050923946"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.atv.17.11.2793", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063334494"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2008.40.4.211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072255766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4143/crt.2008.40.4.211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072255766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079879530", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12", 
    "datePublishedReg": "2014-12-01", 
    "description": "BACKGROUND: Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy. A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma.\nCASE PRESENTATION: A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 \u03bcmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria. His kidney function remained stable. Kidney biopsy findings were consistent with thrombotic microangiopathy. Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved. Due to progression of multiple myeloma, he died a few months later.\nCONCLUSION: In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1471-2369-15-156", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024626", 
        "issn": [
          "1471-2369"
        ], 
        "name": "BMC Nephrology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma", 
    "pagination": "156", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e100a1ed1c0c036c6e3876c53f048e0a544eed553f78fa288565ba918c80d60d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25267524"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967793"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2369-15-156"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1047232947"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2369-15-156", 
      "https://app.dimensions.ai/details/publication/pub.1047232947"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000348_0000000348/records_54316_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2F1471-2369-15-156"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2369-15-156'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2369-15-156'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2369-15-156'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2369-15-156'


 

This table displays all metadata directly associated to this object as RDF triples.

294 TRIPLES      21 PREDICATES      86 URIs      49 LITERALS      37 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2369-15-156 schema:about N09e6aefccc614141ab86e5a64e1f001e
2 N2aad11c752de42caa720158aec8b2281
3 N309027d9fc134ee9b7e1069b86da3ad5
4 N30b341e362f442fa9dc9388970d1c24b
5 N3af2482bec844c39876a7ed0b3998d30
6 N4053167a195c44748fcd2bea846ee27c
7 N42aec73eb2dd491ba3c10ba07c3349a6
8 N474fa84bdbca4218b54c66760287ca39
9 N5f9146c5a37240deb7da084b9ba8d5d6
10 N60ae3ec446de4c5589839cd9b3237daa
11 N69363801428b440687f0eeffd2322529
12 N711fa3fbdc4341b58a9dcc809b445964
13 N753089f55f6d4d839865cd0b82ab0013
14 N790531590cb449118f97a8ff581f2675
15 N7a7961d301b84ee58b1494fe2854a600
16 N81e9a87aa0bd4b9ea905582ac4d19033
17 N8547bfa5228a48358ee0cf6fd2417ae9
18 N8567d2b07f824a6bb38f27017a4621d7
19 Na374f3f7c8c14c9da28a1286c5274ae4
20 Na9b20cd28bdd4bdb8acb0348ec81fd68
21 Nb1b5581bce5c4a97b2148c9c197c7414
22 Nb6f7d295c5ca40b18078edad813c15b5
23 Nbcdc78af758744a4856d214589fdd358
24 Nbe825c02f7c44e85935ba09a59f3beaf
25 Nd81f85d4c09b4a01b7df5108a33bca47
26 Ndec4f822a4d04a19b5492d73b8b57061
27 Nf44e9b77f6324597b392b84171e73ea8
28 Nf5968c278b9b4aec8aa5f732f31cacd0
29 anzsrc-for:11
30 anzsrc-for:1103
31 schema:author Nb2754d0153944530a1516419cdffac01
32 schema:citation sg:pub.10.1007/s12185-008-0140-1
33 sg:pub.10.1038/clpt.1981.154
34 sg:pub.10.1038/nrc780
35 sg:pub.10.1038/sj.bmt.1700791
36 sg:pub.10.1038/sj.bmt.1701171
37 sg:pub.10.1038/sj.bmt.1701830
38 sg:pub.10.1038/sj.bmt.1702849
39 sg:pub.10.1038/sj.ki.5000055
40 sg:pub.10.1046/j.1523-1755.2003.00071.x
41 sg:pub.10.1186/1745-6215-15-107
42 https://app.dimensions.ai/details/publication/pub.1079879530
43 https://doi.org/10.1016/j.beha.2007.09.003
44 https://doi.org/10.1016/j.humpath.2014.05.015
45 https://doi.org/10.1016/j.semnephrol.2010.09.007
46 https://doi.org/10.1046/j.1523-1755.2003.00071.x
47 https://doi.org/10.1056/nejmoa0707330
48 https://doi.org/10.1080/10428190802023707
49 https://doi.org/10.1093/ndt/gft465
50 https://doi.org/10.1093/qjmed/89.10.751
51 https://doi.org/10.1111/j.1445-5994.2011.02458.x
52 https://doi.org/10.1111/petr.12300
53 https://doi.org/10.1136/bcr-2012-006461
54 https://doi.org/10.1158/0008-5472.can-06-4086
55 https://doi.org/10.1161/01.atv.17.11.2793
56 https://doi.org/10.1172/jci115629
57 https://doi.org/10.2215/cjn.02070508
58 https://doi.org/10.3346/jkms.2014.29.5.648
59 https://doi.org/10.4081/hr.2012.e13
60 https://doi.org/10.4143/crt.2008.40.4.211
61 schema:datePublished 2014-12
62 schema:datePublishedReg 2014-12-01
63 schema:description BACKGROUND: Proteasome inhibitors are a relatively new class of chemotherapeutic agents. Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma. However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy. A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma. We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma. CASE PRESENTATION: A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria. His kidney function remained stable. Kidney biopsy findings were consistent with thrombotic microangiopathy. Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved. Due to progression of multiple myeloma, he died a few months later. CONCLUSION: In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.
64 schema:genre research_article
65 schema:inLanguage en
66 schema:isAccessibleForFree true
67 schema:isPartOf N16fca82ea19f467ba9846fcaf92ad5f9
68 N8a9a1fc972854a16991a73178e5b74aa
69 sg:journal.1024626
70 schema:name Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
71 schema:pagination 156
72 schema:productId N64f2d00e308449c9a9d7f81818006257
73 Na6700b504b8e41a69790438360a05a04
74 Nb3e40980117f4683919bdee390c8b375
75 Nc52dc6db1fc141eeaf1a9b129cede2e5
76 Ne43df60b6db648839d0437b928c975bf
77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047232947
78 https://doi.org/10.1186/1471-2369-15-156
79 schema:sdDatePublished 2019-04-11T10:18
80 schema:sdLicense https://scigraph.springernature.com/explorer/license/
81 schema:sdPublisher N6811b12806e84952ad35bfabeaa66049
82 schema:url https://link.springer.com/10.1186%2F1471-2369-15-156
83 sgo:license sg:explorer/license/
84 sgo:sdDataset articles
85 rdf:type schema:ScholarlyArticle
86 N09e6aefccc614141ab86e5a64e1f001e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Proteinuria
88 rdf:type schema:DefinedTerm
89 N16fca82ea19f467ba9846fcaf92ad5f9 schema:volumeNumber 15
90 rdf:type schema:PublicationVolume
91 N1fdbfb1051ae4efd924539763ee375d0 rdf:first sg:person.015017370564.33
92 rdf:rest N37e0a2ef164949dfa0cc0cd5933bf0d6
93 N2aad11c752de42caa720158aec8b2281 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Boronic Acids
95 rdf:type schema:DefinedTerm
96 N309027d9fc134ee9b7e1069b86da3ad5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Oligopeptides
98 rdf:type schema:DefinedTerm
99 N30b341e362f442fa9dc9388970d1c24b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Male
101 rdf:type schema:DefinedTerm
102 N37e0a2ef164949dfa0cc0cd5933bf0d6 rdf:first sg:person.01131201727.91
103 rdf:rest rdf:nil
104 N3af2482bec844c39876a7ed0b3998d30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Dexamethasone
106 rdf:type schema:DefinedTerm
107 N4053167a195c44748fcd2bea846ee27c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Shock, Septic
109 rdf:type schema:DefinedTerm
110 N42aec73eb2dd491ba3c10ba07c3349a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Pyrazines
112 rdf:type schema:DefinedTerm
113 N474fa84bdbca4218b54c66760287ca39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Antineoplastic Agents
115 rdf:type schema:DefinedTerm
116 N5f9146c5a37240deb7da084b9ba8d5d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Teniposide
118 rdf:type schema:DefinedTerm
119 N60ae3ec446de4c5589839cd9b3237daa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Disease Progression
121 rdf:type schema:DefinedTerm
122 N64f2d00e308449c9a9d7f81818006257 schema:name nlm_unique_id
123 schema:value 100967793
124 rdf:type schema:PropertyValue
125 N6811b12806e84952ad35bfabeaa66049 schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 N69363801428b440687f0eeffd2322529 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Acute Kidney Injury
129 rdf:type schema:DefinedTerm
130 N711fa3fbdc4341b58a9dcc809b445964 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Combined Modality Therapy
132 rdf:type schema:DefinedTerm
133 N753089f55f6d4d839865cd0b82ab0013 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Hypertension, Renal
135 rdf:type schema:DefinedTerm
136 N790531590cb449118f97a8ff581f2675 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Proteasome Inhibitors
138 rdf:type schema:DefinedTerm
139 N7a7961d301b84ee58b1494fe2854a600 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Thrombotic Microangiopathies
141 rdf:type schema:DefinedTerm
142 N81e9a87aa0bd4b9ea905582ac4d19033 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Thalidomide
144 rdf:type schema:DefinedTerm
145 N8547bfa5228a48358ee0cf6fd2417ae9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Recurrence
147 rdf:type schema:DefinedTerm
148 N8567d2b07f824a6bb38f27017a4621d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Lenalidomide
150 rdf:type schema:DefinedTerm
151 N8a9a1fc972854a16991a73178e5b74aa schema:issueNumber 1
152 rdf:type schema:PublicationIssue
153 Na374f3f7c8c14c9da28a1286c5274ae4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Multiple Myeloma
155 rdf:type schema:DefinedTerm
156 Na6700b504b8e41a69790438360a05a04 schema:name doi
157 schema:value 10.1186/1471-2369-15-156
158 rdf:type schema:PropertyValue
159 Na9b20cd28bdd4bdb8acb0348ec81fd68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Cyclophosphamide
161 rdf:type schema:DefinedTerm
162 Nb1b5581bce5c4a97b2148c9c197c7414 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Podocytes
164 rdf:type schema:DefinedTerm
165 Nb2754d0153944530a1516419cdffac01 rdf:first sg:person.01027631644.51
166 rdf:rest N1fdbfb1051ae4efd924539763ee375d0
167 Nb3e40980117f4683919bdee390c8b375 schema:name readcube_id
168 schema:value e100a1ed1c0c036c6e3876c53f048e0a544eed553f78fa288565ba918c80d60d
169 rdf:type schema:PropertyValue
170 Nb6f7d295c5ca40b18078edad813c15b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Middle Aged
172 rdf:type schema:DefinedTerm
173 Nbcdc78af758744a4856d214589fdd358 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Bortezomib
175 rdf:type schema:DefinedTerm
176 Nbe825c02f7c44e85935ba09a59f3beaf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Edema
178 rdf:type schema:DefinedTerm
179 Nc52dc6db1fc141eeaf1a9b129cede2e5 schema:name pubmed_id
180 schema:value 25267524
181 rdf:type schema:PropertyValue
182 Nd81f85d4c09b4a01b7df5108a33bca47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Fatal Outcome
184 rdf:type schema:DefinedTerm
185 Ndec4f822a4d04a19b5492d73b8b57061 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Humans
187 rdf:type schema:DefinedTerm
188 Ne43df60b6db648839d0437b928c975bf schema:name dimensions_id
189 schema:value pub.1047232947
190 rdf:type schema:PropertyValue
191 Nf44e9b77f6324597b392b84171e73ea8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Antineoplastic Combined Chemotherapy Protocols
193 rdf:type schema:DefinedTerm
194 Nf5968c278b9b4aec8aa5f732f31cacd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Hematopoietic Stem Cell Transplantation
196 rdf:type schema:DefinedTerm
197 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
198 schema:name Medical and Health Sciences
199 rdf:type schema:DefinedTerm
200 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
201 schema:name Clinical Sciences
202 rdf:type schema:DefinedTerm
203 sg:journal.1024626 schema:issn 1471-2369
204 schema:name BMC Nephrology
205 rdf:type schema:Periodical
206 sg:person.01027631644.51 schema:affiliation https://www.grid.ac/institutes/grid.266623.5
207 schema:familyName Hobeika
208 schema:givenName Liliane
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027631644.51
210 rdf:type schema:Person
211 sg:person.01131201727.91 schema:affiliation https://www.grid.ac/institutes/grid.259828.c
212 schema:familyName Velez
213 schema:givenName Juan Carlos Q
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01131201727.91
215 rdf:type schema:Person
216 sg:person.015017370564.33 schema:affiliation https://www.grid.ac/institutes/grid.259828.c
217 schema:familyName Self
218 schema:givenName Sally E
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015017370564.33
220 rdf:type schema:Person
221 sg:pub.10.1007/s12185-008-0140-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032870534
222 https://doi.org/10.1007/s12185-008-0140-1
223 rdf:type schema:CreativeWork
224 sg:pub.10.1038/clpt.1981.154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040267576
225 https://doi.org/10.1038/clpt.1981.154
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/nrc780 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024581782
228 https://doi.org/10.1038/nrc780
229 rdf:type schema:CreativeWork
230 sg:pub.10.1038/sj.bmt.1700791 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038194035
231 https://doi.org/10.1038/sj.bmt.1700791
232 rdf:type schema:CreativeWork
233 sg:pub.10.1038/sj.bmt.1701171 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006660654
234 https://doi.org/10.1038/sj.bmt.1701171
235 rdf:type schema:CreativeWork
236 sg:pub.10.1038/sj.bmt.1701830 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037910558
237 https://doi.org/10.1038/sj.bmt.1701830
238 rdf:type schema:CreativeWork
239 sg:pub.10.1038/sj.bmt.1702849 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050017834
240 https://doi.org/10.1038/sj.bmt.1702849
241 rdf:type schema:CreativeWork
242 sg:pub.10.1038/sj.ki.5000055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020678317
243 https://doi.org/10.1038/sj.ki.5000055
244 rdf:type schema:CreativeWork
245 sg:pub.10.1046/j.1523-1755.2003.00071.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1012605076
246 https://doi.org/10.1046/j.1523-1755.2003.00071.x
247 rdf:type schema:CreativeWork
248 sg:pub.10.1186/1745-6215-15-107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026028815
249 https://doi.org/10.1186/1745-6215-15-107
250 rdf:type schema:CreativeWork
251 https://app.dimensions.ai/details/publication/pub.1079879530 schema:CreativeWork
252 https://doi.org/10.1016/j.beha.2007.09.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025914764
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1016/j.humpath.2014.05.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034050093
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1016/j.semnephrol.2010.09.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019546282
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1046/j.1523-1755.2003.00071.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1012605076
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1056/nejmoa0707330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036840499
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1080/10428190802023707 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009669974
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1093/ndt/gft465 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028765304
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1093/qjmed/89.10.751 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031036405
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1111/j.1445-5994.2011.02458.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1035735607
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1111/petr.12300 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033543085
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1136/bcr-2012-006461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011174364
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1158/0008-5472.can-06-4086 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047843351
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1161/01.atv.17.11.2793 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063334494
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1172/jci115629 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050923946
279 rdf:type schema:CreativeWork
280 https://doi.org/10.2215/cjn.02070508 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038375943
281 rdf:type schema:CreativeWork
282 https://doi.org/10.3346/jkms.2014.29.5.648 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013160147
283 rdf:type schema:CreativeWork
284 https://doi.org/10.4081/hr.2012.e13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028803821
285 rdf:type schema:CreativeWork
286 https://doi.org/10.4143/crt.2008.40.4.211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072255766
287 rdf:type schema:CreativeWork
288 https://www.grid.ac/institutes/grid.259828.c schema:alternateName Medical University of South Carolina
289 schema:name Department of Pathology, Medical University of South Carolina, Charleston, SC, USA
290 Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA
291 rdf:type schema:Organization
292 https://www.grid.ac/institutes/grid.266623.5 schema:alternateName University of Louisville
293 schema:name Division of Nephrology and Hypertension, Department of Medicine, University of Louisville, 615 South Preston Street, 40202, Louisville, KY, USA
294 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...